Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) have received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $20.17.

A number of equities research analysts have commented on the company. S&P Equity Research increased their price target on Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. William Blair reiterated a “buy” rating and issued a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. RBC Capital Markets reiterated a “sector perform” rating and issued a $16.00 price target on shares of Dynavax Technologies Corp. in a research note on Wednesday, September 7th. Zacks Investment Research cut Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, November 10th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th.

Dynavax Technologies Corp. (NASDAQ:DVAX) opened at 4.70 on Thursday. Dynavax Technologies Corp. has a 52-week low of $3.20 and a 52-week high of $29.86. The stock’s market capitalization is $181.08 million. The stock’s 50 day moving average price is $9.63 and its 200-day moving average price is $13.43.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.15. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $2.44 million. Dynavax Technologies Corp. had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. The company’s revenue for the quarter was down 83.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.82) earnings per share. On average, equities analysts expect that Dynavax Technologies Corp. will post ($3.21) EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in DVAX. CAM Group Holding A S boosted its stake in Dynavax Technologies Corp. by 18.8% in the second quarter. CAM Group Holding A S now owns 189,962 shares of the biopharmaceutical company’s stock worth $2,770,000 after buying an additional 30,000 shares during the period. GW&K Investment Management LLC raised its position in shares of Dynavax Technologies Corp. by 13.3% in the second quarter. GW&K Investment Management LLC now owns 160,213 shares of the biopharmaceutical company’s stock worth $2,336,000 after buying an additional 18,794 shares in the last quarter. Boston Advisors LLC raised its position in shares of Dynavax Technologies Corp. by 1.3% in the second quarter. Boston Advisors LLC now owns 12,330 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 155 shares in the last quarter. Falcon Point Capital LLC raised its position in shares of Dynavax Technologies Corp. by 12.7% in the second quarter. Falcon Point Capital LLC now owns 21,753 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 2,458 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Dynavax Technologies Corp. during the second quarter worth $107,000. Institutional investors own 85.18% of the company’s stock.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Stock Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related stocks with our FREE daily email newsletter.